Sarborg Expands Quantum Computing IP into Drug Discovery, CDT Holds 22.7% Stake — CDT Equity Inc.

Event summary

Sarborg filed new IP applying quantum sampling to disease biology and drug discovery on September 29, 2026.
CDT Equity holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital.
Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.
Sarborg is in active discussions with a leading global quantum computing company for a partnership.
The model found combinatorially regulated genes concentrate cell-surface receptors and ion channels, among the most targeted opportunities in pharmacology.

The big picture

Sarborg’s expansion into quantum computing applications for drug discovery marks a strategic shift in leveraging quantum sampling to solve complex biological problems. This move aligns with broader industry trends where quantum computing is increasingly seen as a tool to enhance drug discovery processes. CDT’s significant stake in Sarborg positions it to benefit from the potential commercialization of these advanced models, though the success will depend on the execution of partnerships and the scalability of the technology.

What we're watching

Partnership Execution: Whether Sarborg can secure and operationalize a partnership with a leading quantum computing company to advance its models on market-leading hardware.
Valuation Impact: The pace at which Sarborg’s expanding IP portfolio and strategic partnerships will influence its valuation and CDT’s stake.
Commercialization Timing: How quickly Sarborg can transition its quantum-enhanced models from research to commercially usable outputs in drug discovery.